{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:51:06Z","timestamp":1773337866935,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"crossref","award":["HHSN272201300033C"],"award-info":[{"award-number":["HHSN272201300033C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"crossref","award":["HHSN272201600012C"],"award-info":[{"award-number":["HHSN272201600012C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068614"],"award-info":[{"award-number":["UM1 AI068614"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068618"],"award-info":[{"award-number":["UM1 AI068618"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"US Public Health Service","award":["UM1 AI069453"],"award-info":[{"award-number":["UM1 AI069453"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1017604"],"award-info":[{"award-number":["OPP1017604"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008091","name":"University of Rochester","doi-asserted-by":"publisher","award":["UM1"],"award-info":[{"award-number":["UM1"]}],"id":[{"id":"10.13039\/100008091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008091","name":"University of Rochester","doi-asserted-by":"publisher","award":["AI069511"],"award-info":[{"award-number":["AI069511"]}],"id":[{"id":"10.13039\/100008091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>HVTN 120 is a phase 1\/2a randomized double-blind placebo-controlled human immunodeficiency virus (HIV) vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent subtype C gp120 Env protein at 2 dose levels in healthy HIV-uninfected adults.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants received ALVAC-HIV (vCP2438) alone or placebo at months 0 and 1. At months 3 and 6, participants received either placebo, ALVAC-HIV (vCP2438) with 200\u2005\u03bcg of bivalent subtype C gp120 adjuvanted with MF59 or AS01B, or ALVAC-HIV (vCP2438) with 40\u2005\u03bcg of bivalent subtype C gp120 adjuvanted with AS01B. Primary outcomes were safety and immune responses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We enrolled 160 participants, 55% women, 18\u201340 years old (median age 24 years) of whom 150 received vaccine and 10 placebo. Vaccines were generally safe and well tolerated. At months 6.5 and 12, CD4+ T-cell response rates and magnitudes were higher in the AS01B-adjuvanted groups than in the MF59-adjuvanted group. At month 12, HIV-specific Env-gp120 binding antibody response magnitudes in the 40\u2005\u03bcg gp120\/AS01B group were higher than in either of the 200\u2005\u03bcg gp120 groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The 40\u2005\u03bcg dose gp120\/AS01B regimen elicited the highest CD4+ T-cell and binding antibody responses.<\/jats:p>\n                  <jats:p>Clinical Trials Registration . NCT03122223.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiad434","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T13:09:59Z","timestamp":1696511399000},"page":"e405-e415","source":"Crossref","is-referenced-by-count":7,"title":["Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120"],"prefix":"10.1093","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-5150","authenticated-orcid":false,"given":"Zvavahera Mike","family":"Chirenje","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of California San Francisco , San Francisco, California , USA"},{"name":"Faculty of Medicine and Health Science, University of Zimbabwe Clinical Trials Research Centre, University of Zimbabwe , Harare , Zimbabwe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Laher","sequence":"additional","affiliation":[{"name":"Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg , South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"One","family":"Dintwe","sequence":"additional","affiliation":[{"name":"Cape Town HIV Vaccine Trials Network Immunology Laboratory , Cape Town , South Africa"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monde","family":"Muyoyeta","sequence":"additional","affiliation":[{"name":"Centre for Infectious Diseases Research in Zambia , Livingstone , Zambia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan C","family":"deCamp","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zonglin","family":"He","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Grunenberg","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faatima","family":"Laher Omar","sequence":"additional","affiliation":[{"name":"Cape Town HIV Vaccine Trials Network Immunology Laboratory , Cape Town , South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly E","family":"Seaton","sequence":"additional","affiliation":[{"name":"Center for Human Systems Immunology, Duke University School of Medicine , Durham, North Carolina , USA"},{"name":"Department of Surgery, Duke University Medical Center , Durham, North Carolina , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Polakowski","sequence":"additional","affiliation":[{"name":"Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda S","family":"Woodward Davis","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Maganga","sequence":"additional","affiliation":[{"name":"National Institute for Medical Research-Mbeya Medical Research Centre , Mbeya , Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey R","family":"Baden","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women's Hospital , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Mayer","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard University , Boston, Massachusetts , USA"},{"name":"The Fenway Institute, Fenway Health , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyros","family":"Kalams","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Keefer","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Rochester , Rochester, NewYork , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srilatha","family":"Edupuganti","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University , Atlanta, Georgia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benigno","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University\/University Hospitals, Cleveland Medical Center , Cleveland, Ohio , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Frank","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Pennsylvania , Philadelphia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyman","family":"Scott","sequence":"additional","affiliation":[{"name":"SanFrancisco Department of Public Health , San Francisco, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"Stranix-Chibanda","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Science, University of Zimbabwe Clinical Trials Research Centre, University of Zimbabwe , Harare , Zimbabwe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Gurunathan","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur , Swiftwater, Pennsylvania , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marguerite","family":"Koutsoukos","sequence":"additional","affiliation":[{"name":"GSK , Wavre , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Van Der Meeren","sequence":"additional","affiliation":[{"name":"GSK , Rixensart , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A","family":"DiazGranados","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur , Swiftwater, Pennsylvania , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Paez","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Andersen-Nissen","sequence":"additional","affiliation":[{"name":"Cape Town HIV Vaccine Trials Network Immunology Laboratory , Cape Town , South Africa"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-3741","authenticated-orcid":false,"given":"James","family":"Kublin","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University Medical Center , Durham, North Carolina , USA"},{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Tomaras","sequence":"additional","affiliation":[{"name":"Center for Human Systems Immunology, Duke University School of Medicine , Durham, North Carolina , USA"},{"name":"Department of Surgery, Duke University Medical Center , Durham, North Carolina , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Juliana","family":"McElrath","sequence":"additional","affiliation":[{"name":"Cape Town HIV Vaccine Trials Network Immunology Laboratory , Cape Town , South Africa"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"2024081523515864700_jiad434-B1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"New Engl J Med"},{"key":"2024081523515864700_jiad434-B2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"New Engl J Med"},{"key":"2024081523515864700_jiad434-B3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120\u2013MF59 in adults","volume":"384","author":"Gray","year":"2021","journal-title":"New Engl J Med"},{"key":"2024081523515864700_jiad434-B4","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00705-020-04777-2","article-title":"Review of preventative HIV vaccine clinical trials in South Africa","volume":"165","author":"Laher","year":"2020","journal-title":"Arch Virol"},{"key":"2024081523515864700_jiad434-B5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/422258","article-title":"Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults","volume":"190","author":"Nitayaphan","year":"2004","journal-title":"J Infect Dis"},{"key":"2024081523515864700_jiad434-B6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fimmu.2013.00214","article-title":"Vaccine adjuvants: mode of action","volume":"4","author":"Gregorio","year":"2013","journal-title":"Front Immunol"},{"key":"2024081523515864700_jiad434-B7","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1073\/pnas.0804699105","article-title":"Molecular and cellular signatures of human vaccine adjuvants","volume":"105","author":"Mosca","year":"2008","journal-title":"Proc National Acad Sci"},{"key":"2024081523515864700_jiad434-B8","doi-asserted-by":"crossref","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci Transl Med"},{"key":"2024081523515864700_jiad434-B9","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","article-title":"The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells","volume":"180","author":"Seubert","year":"2008","journal-title":"J Immunol"},{"key":"2024081523515864700_jiad434-B10","first-page":"235","volume-title":"Vaccine adjuvants: immunological and clinical principles","author":"Baldridge","year":"2008"},{"key":"2024081523515864700_jiad434-B11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/intimm\/12.6.807","article-title":"The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells","volume":"12","author":"De Becker","year":"2000","journal-title":"Int Immunol"},{"key":"2024081523515864700_jiad434-B12","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, An aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"2024081523515864700_jiad434-B13","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4049\/jimmunol.168.2.926","article-title":"Monophosphoryl lipid A activates both human dendritic cells and T-cells","volume":"168","author":"Ismaili","year":"2002","journal-title":"J Immunol"},{"key":"2024081523515864700_jiad434-B14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","article-title":"Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex","volume":"146","author":"Kensil","year":"1991","journal-title":"J Immunol"},{"key":"2024081523515864700_jiad434-B15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Gar\u00e7on","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"2024081523515864700_jiad434-B16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1586\/erv.11.18","article-title":"Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer","volume":"10","author":"Ragupathi","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"2024081523515864700_jiad434-B17","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/S0264-410X(00)00415-1","article-title":"QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans","volume":"19","author":"Evans","year":"2001","journal-title":"Vaccine"},{"key":"2024081523515864700_jiad434-B18","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"New Engl J Med"},{"key":"2024081523515864700_jiad434-B19","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Partnership R S Clinical Trials","year":"2011","journal-title":"New Engl J Med"},{"key":"2024081523515864700_jiad434-B20","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia","volume":"82","author":"Tomaras","year":"2008","journal-title":"J Virol"},{"key":"2024081523515864700_jiad434-B21","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01843-17","article-title":"HIV-1 Envelope glycoproteins from diverse clades differentiate antibody responses and durability among vaccinees","volume":"92","author":"Yates","year":"2018","journal-title":"J Virol"},{"key":"2024081523515864700_jiad434-B22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","author":"Yates","year":"2014","journal-title":"Sci Transl Med"},{"key":"2024081523515864700_jiad434-B23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jim.2007.02.003","article-title":"Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials","volume":"322","author":"Bull","year":"2007","journal-title":"J Immunol Methods"},{"key":"2024081523515864700_jiad434-B24","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/cyto.a.22218","article-title":"OMIP-014: validated multifunctional characterization of antigen-specific human T-cells by intracellular cytokine staining","volume":"81A","author":"DeRosa","year":"2012","journal-title":"Cytom Part A"},{"key":"2024081523515864700_jiad434-B25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2007.03.002","article-title":"Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T-cells induced by vaccination","volume":"323","author":"Horton","year":"2007","journal-title":"J Immunol Methods"},{"key":"2024081523515864700_jiad434-B26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/cyto.a.21084","article-title":"High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses","volume":"79","author":"Pollara","year":"2011","journal-title":"Cytometry A"},{"key":"2024081523515864700_jiad434-B27","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.1128\/JVI.73.11.8966-8974.1999","article-title":"A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor","volume":"73","author":"Trkola","year":"1999","journal-title":"J Virol"},{"key":"2024081523515864700_jiad434-B28","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nbt.3187","article-title":"COMPASS identifies T-cell subsets correlated with clinical outcomes","volume":"33","author":"Lin","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2024081523515864700_jiad434-B29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/infdis\/jiac260","article-title":"Analysis of the HIV vaccine trials network 702 phase 2b\u20133 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk","volume":"226","author":"Moodie","year":"2022","journal-title":"J Infect Dis"},{"key":"2024081523515864700_jiad434-B30","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S2352-3018(18)30071-7","article-title":"Subtype C ALVAC-HIV and bivalent subtype C gp120\/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1\/2 trial","volume":"5","author":"Bekker","year":"2018","journal-title":"Lancet Hiv"},{"key":"2024081523515864700_jiad434-B31","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/cid\/ciq160","article-title":"An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T-cell responses in seronegative volunteers","volume":"52","author":"Braeckel","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"2024081523515864700_jiad434-B32","doi-asserted-by":"crossref","first-page":"e25793","DOI":"10.1002\/jia2.25793","article-title":"Current approaches to HIV vaccine development: a narrative review","volume":"24","author":"Kim","year":"2021","journal-title":"J Int Aids Soc"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad434\/53689401\/jiad434.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/2\/e405\/58808581\/jiad434.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/2\/e405\/58808581\/jiad434.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T23:53:30Z","timestamp":1723766010000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/230\/2\/e405\/7289550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,10,5]]},"published-print":{"date-parts":[[2024,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad434","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8,15]]},"published":{"date-parts":[[2023,10,5]]}}}